Increasing
multidrug resistance in Neisseria gonorrheae is a
growing public health crisis. Resistance to the last line therapies,
cephalosporins and azithromycin, are of particular concern, fueling
the need to discover new treatments. Here, we identified the phosphoglycolipid
moenomycin from a screen of microbial natural products against drug-resistant N. gonorrheae as a potent antigonococcal agent. Moenomycin
demonstrates excellent activity (MIC = 0.004–0.03 μg/mL)
against a variety of multidrug-resistant N. gonorrheae. Importantly, moenomycin, thought to be a Gram-positive specific
antibiotic, penetrates the Gram-negative gonococcal outer membrane.
Moenomycin causes intracellular accumulation of peptidoglycan precursors,
cell blebbing, and rupture of the cell envelope, all consistent with
cell wall biosynthesis inhibition. Serial bacterial exposure to moenomycin
for 14 days revealed slow development of resistance (MICDay14 = 0.03–0.06 μg/mL), unlike the clinically used drug
azithromycin. Our results offer the potential utility of moenomycin
as a lead for antigonococcal therapeutic candidates and warrant further
investigation.